|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Influenza vaccination in acute coronary syndromes patients in Thailand: the cost-effectiveness analysis of the prevention for cardiovascular events and pneumonia显示文摘BackgroundInfluenza 种痘临床上被显示了在急性冠的症候群(交流) 减少不利心血管的结果病人,而是经济观点能提供重要数据使决定明智。试图为心血管的事件和生长得很好的肺病 prevention.MethodsLifetime 费用,预期寿命,和调整质量的生活年( QALY )执行终生的年度流行性感冒种痘的经济评估的这研究在上的一个六健康的状态 Markov 模型条件的一个年周期长度以外被估计为交流的一个住院,中风,心失败,肺病,没有住院发生了,或死亡。40-year-old-and-above, 50-year-old-and-above,和 65-year-old-and-above 情形的三年龄组的比较被执行。增长划算比率(ICER ) 和网钱的利益(NMB ) 在 2016 表现为一个社会观点。模型坚韧性被单程、概率的敏感 analyses.ResultsThe 流行性感冒种痘决定在所有年龄组是划算的,由比泰国的可接受的 willingness-to-pay 阀值完全低的主导的 ICER (有更高的有效性的更低的费用)[ 160,000 THB ( 4,466.8 美金)每 QALY ],与 NMB 的大增长价值。特别,当大多数每年为每 patient.ConclusionsThe 在 129,092 THB (3,603.9 美金) 受益, 50-year-old-and-above 情形被显示出到在交流的标准处理的另外的流行性感冒种痘在所有年龄组是划算的,它应该在临床的实践和健康政策做过程被考虑。 | Apirak Sribhutom Arintaya Phrommintikul Wanwarang Wongcharoen Usa Chaikledkaew Suntara Eakanunkul Apichard Sukonthasam | 2018 | Journal of Geriatric Cardiology2018，15，6： | 9 |
| 2 | Electrocardiographic predictors of cardiovascular events in patients at high cardiovascular risk: a multicenter study显示文摘Background There are limited data on the prevalence of electrocardiographic (ECG) abnormalities, and their value for predicting a major adverse cardiovascular event (MACE) in patients at high cardiovascular risk. This study aimed to determine the prevalence of ECG abnormalities in patients at high risk for cardiovascular events, and to identify ECG abnormalities that significantly predict MACE. Methods Patients aged ≥ 45 years with established atherosclerotic disease (EAD) were consecutively enrolled from the outpatient clinics of the six participating hospitals during April 2011 to March 2014. The following data were collected: demographic data, cardiovascular risk factors, history of cardiovascular event, physical examination, ECG and medications. ECG was analyzed using Minnesota Code criteria. MACE included cardiovascular death, non-fatal myocardial infarction, and hospitalization due to unstable angina or heart failure. Results A total of 2009 patients were included, 1048 patients (52.2%) had established EAD, and 961 patients (47.8%) had multiple risk factors (MRF). ECG abnormalities included atrial fibrillation (6.7%), premature ventricular contraction (5.4%), pathological Q-wave (Q/QS)(21.3%), T-wave inversion (20.0%), intraventricular ventricular conduction delay (IVCD)(7.3%), left ventricular hypertrophy (LVH)(12.2%), and AV block (12.5%). MACE occurred in 88 patients (4.4%). Independent predictors of MACE were chronic kidney disease, EAD, and the presence of atrial fibrillation, Q/QS, IVCD or LVH by ECG. Conclusions A high prevalence of ECG abnormalities was found. The prevalence of ECG abnormalities was high even among those with risk factors without documented cardiovascular disease. | Rungroj Krittayaphong Muenpetch Muenkaew Polakit Chiewvit Nithima Ratanasit Yodying Kaolawanich Arintaya Phrommintikul | 2019 | Journal of Geriatric Cardiology2019，16，8： | 3 |
| 3 | PPARγ activator,rosiglitazone:Is it beneficial or harmful to the cardiovascular system?显示文摘Rosiglitazone is a synthetic agonist of peroxisome proliferator-activated receptor γ which is used to improve insulin resistance in patients with typeⅡdiabetes.Rosiglitazone exerts its glucose-lowering effects by improving insulin sensitivity.Data from various studies in the past decade suggest that the therapeutic effects of rosiglitazone reach far beyond its use as an insulin sensitizer since it also has other benefits on the cardiovascular system such as improvement of contractile dysfunction,inhibition of the inflammatory response by reducing neutrophil and macrophage accumulation,and the protection of myocardial injury during ischemic/reperfusion in different animal models.Previous clinical studies in typeⅡdiabetes patients demonstrated that rosiglitazone played an important role in protectingagainst arteriosclerosis by normalizing the metabolic disorders and reducing chronic inflammation of the vascular system.Despite these benefits,inconsistent findings have been reported,and growing evidence has demonstrated adverse effects of rosiglitazone on the cardiovascular system,including increased risk of acute myocardial infarction,heart failure and chronic heart failure.As a result,rosiglitazone has been recently withdrawn from EU countries.Nevertheless,the effect of rosiglitazone on ischemic heart disease has not yet been firmly established.Future prospective clinical trials designed for the specific purpose of establishing the cardiovascular benefit or risk of rosiglitazone would be the best way to resolve the uncertainties regarding the safety of rosiglitazone in patients with heart disease. | Siripong Palee Siriporn Chattipakorn Arintaya Phrommintikul Nipon Chattipakorn | 2011 | World Journal of Cardiology2011，3，5： | 3 |
| 4 | Rate of anticoagulant use, and factors associated with not prescribing anticoagulant in older Thai adults with non-valvular atrial fibrillation: A multicenter registry显示文摘Objectives To investigate the rate of anticoagulant use,the reasons for not prescribing anticoagulant,and the factors associated with non-prescription of anticoagulant in older Thai adults with non-valvular atrial fibrillation.Methods A multicenter registry of patients with non-valvular atrial fibrillation was conducted during 2014 to 2017 in Thailand.Demographic,medical history,antithrombotic medication,non-antithrombotic medication,and laboratory data were collected and analyzed.Data were compared between the older adult (≥ 65 years) and younger adult (< 65 years) groups.The reasons why anticoagulant was not prescribed were collected,and predictive factors were identified.Results A total of 3218 patients (1873 males) with an average age of 67.3 ± 11.3 years were included.Almost two-thirds (61.0%) of patients were in the older adult group.Anticoagulant was prescribed in 2422 patients (75.3%): 81.4% in the older adult group and 65.7% in the younger adult group.The three main reasons for not prescribing anticoagulant were already taking antiplatelets,patient refusal,and bleeding risk.These reasons were more common in older adults as compared to younger adults.Multivariate analysis revealed current use of antiplatelets to be the most important factor that predict the non-prescription of anticoagulant in older population.Conclusions The prevalence of anticoagulant prescription among older Thai adults with atrial fibrillation is 81.4%.Taking antiplatelet drugs was found to be the strongest reason that predicts the non-prescription of anticoagulant in this patient population.A guideline should be developed to optimize the use of anticoagulant and antiplatelet in older adults. | Rungroj Krittayaphong Arintaya Phrommintikul Pornchai Ngamjanyaporn Khanchai Siriwattana Wiwat Kanjanarutjawiwat Thoranis Chantrarat Roj Rojjarekampai Pontawee Kaewcomdee Patthrapon Sonkhammee | 2019 | Journal of Geriatric Cardiology2019，16，3： | 3 |
| 5 | Mortality and target haemoglobin concetrat ions in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis显示文摘 | Phrommintikul A Haas S J Elsik M | 2007 | Lancet2007，369，： | 1 |
| 6 | Complete right bundle branch block predicts mortality in Thai patients with chronic heart failure with reduced ejection fraction显示文摘 | Wongcharoen W Phrommintikul A Kanjanavanit R | 2010 | J Med Assoc Thai2010，93，4： | 1 |
| 7 | Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats 显示文摘 | KEMP W KOMPA A PHROMMINTIKUL A | 2009 | Am J Physiol Gastrointest Liver Physiol2009，297，4： | 1 |
| 8 | Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta- analysis显示文摘 | Phrommintikul A Haas SJ | 2007 | Lancet2007，369，9559： | 1 |
| 9 | Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction显示文摘 | Phrommintikul A Tran L Kompa A | 2008 | Am J Physiol Heart Circ Physiol2008，294，4： | 1 |
| 10 | Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping显示文摘 | Iles L Pfluger H Phrommintikul A | 2008 | J Am Coll Cardiol2008，52，19： | 1 |
| 11 | Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia显示文摘 | Phrommintikul A Sukonthasarn A Kanjanavanit R | 2006 | Heart2006，92，10： | 1 |
| 12 | Mortality and Target Haemoglobin Concentrations in Anaemic Patients with Chronic Kidney Disease Treated with Erythropoietin: a Metaanalysis显示文摘 | Phrommintikul A Haas S J Elsik M | 2007 | Lancet2007，369，9559： | 1 |
| 13 | Matrix metalloproteinases and myocardial infarction显示文摘 | Phatharajaree W Phrommintikul A Chattipakom N | 2007 | Can J Cardiol2007，23，9： | 1 |
| 14 | Matrix metallo- proteinases and myocardial infarction 显示文摘 | Phatharajaree W Phrommintikul A Chattipakom N | 2007 | Can J Cardiol2007，23，9： | 1 |
| 15 | Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin : a meta-analysis显示文摘 | Phrommintikul A Haas S J Elsik M | 2007 | Lancet2007，369，9559： | 1 |
| 16 | Matrix metalloproteinases and myocardial infarction显示文摘 | Phatharajaree W Phrommintikul A Chattipakorn | 2007 | Can J Cardiol2007，23，9： | 1 |
| 17 | Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping显示文摘 | Iles L Pfluger H Phrommintikul A | | 0，，： | 1 |
| 18 | The protective role of eureumin in cardiovascular diseases显示文摘 | Wongcharoen W Phrommintikul A | 2009 | Int J Cardiol2009，133，2： | 1 |
| 19 | Utility of Myocardial Fibrosis and Fatty Infiltration Detected by Cardiac Magnetic Resonance Imaging in the Diagnosis of Arrhythmogenic Right Ventricular Dysplasia—A Single Centre Experience显示文摘 | Heinz B. Pfluger Arintaya Phrommintikul Justin A. Mariani Joshi G. Cherayath Andrew J. Taylor | 2008 | Heart, Lung and Circulation2008，，： | 1 |
| 20 | Chronic urotensin-Ⅱ infusion induces diastolic dysfunction and enhances collagen production in rats显示文摘 | Tran L Kompa AR Kemp W Phrommintikul A Wang BH Krum H | 2010 | Am J Physiol Heart Circ Physiol2010，298，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员